Despite the associations of GPR56 with poor prognosis in several different cancer entities (Shashidhar et al, 2005; Kausar et al, 2011) and endothelial‐to‐hematopoietic transition (Solaimani Kartalaei et al, 2015), it was unclear whether and how GPR56 was functionally involved in LSC activity in human AML and how its downstream pathways might be targeted. The gene discussed is ADGRG1; the disease is cancer.